Skip to main content
. 2021 Nov 13;13(3):717–737. doi: 10.1016/j.jcmgh.2021.11.003

Figure 11.

Figure 11

Cimetidine administration suppressed neutrophil maturation and promoted inflammation-associated colon cancer. (A and B) Gene expression of MYC targets and surface markers in the cimetidine-treated and control LDNs (n = 4). (C) Representative immunofluorescence staining (magnification: 400× and 1000×) of S100A8 (green) and TLR4 (red) in LDNs from the cimetidine-treated and control mice. (D) Cell-cycle analysis of bone marrow cells from the cimetidine-treated and control mice (n = 5). (E) Tumors in the middle colon examined by a colonoscopy (top), macroscopic observation of the colon (bottom, n = 8). (F) Tumor numbers counted under a dissecting microscope (n = 8). (G and H) Rectal SM was observed (magnification: 40× and 200×) after 2 cycles of DSS treatment in the cimetidine-treated mice (n = 7), but not in the control mice (n = 9). (I and J) Immunofluorescence staining (magnification: 200× and 400×) of S100A8 (green) and PD-L1 (red) in the tumors of the cimetidine-treated (n = 6) and control (n = 6) mice. (K) Suppression of CD8+ T-cell proliferation by cimetidine-treated and control HDNs (n = 3). All values are means ± SD. (A and B) P values are shown under the panels. ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001. Cim, cimetidine; Ctrl, control; DAPI, 4′,6-diamidino-2-phenylindole; PC, positive control.